With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic […]

The post Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now appeared first on Trak.in - Indian Business of Tech, Mobile & Startups.